J. Safra Sarasin Holding AG Lowers Stock Position in Laboratory Co. of America Holdings (NYSE:LH)

J. Safra Sarasin Holding AG trimmed its position in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 70.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,263 shares of the medical research company's stock after selling 5,479 shares during the period. J. Safra Sarasin Holding AG's holdings in Laboratory Co. of America were worth $519,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Graney & King LLC acquired a new position in shares of Laboratory Co. of America during the fourth quarter worth $26,000. Fortitude Family Office LLC increased its position in Laboratory Co. of America by 312.5% during the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company's stock valued at $30,000 after buying an additional 100 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in Laboratory Co. of America by 309.8% in the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company's stock valued at $39,000 after buying an additional 127 shares during the last quarter. Human Investing LLC acquired a new stake in Laboratory Co. of America in the fourth quarter worth about $39,000. Finally, Heck Capital Advisors LLC purchased a new stake in shares of Laboratory Co. of America during the fourth quarter worth about $44,000. Institutional investors own 95.94% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on LH. Evercore ISI upgraded shares of Laboratory Co. of America from an "in-line" rating to an "outperform" rating and increased their price target for the stock from $260.00 to $265.00 in a report on Tuesday, January 7th. Jefferies Financial Group raised their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Barclays cut their price target on Laboratory Co. of America from $260.00 to $240.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Truist Financial decreased their price objective on Laboratory Co. of America from $285.00 to $274.00 and set a "buy" rating for the company in a report on Friday, April 11th. Finally, UBS Group dropped their target price on Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $268.77.

Insider Activity at Laboratory Co. of America

In related news, CMO Amy B. Summy sold 226 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $250.40, for a total transaction of $56,590.40. Following the sale, the chief marketing officer now owns 4,544 shares in the company, valued at approximately $1,137,817.60. This trade represents a 4.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kerrii B. Anderson sold 500 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $255.63, for a total value of $127,815.00. Following the completion of the transaction, the director now owns 13,166 shares of the company's stock, valued at $3,365,624.58. This trade represents a 3.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,258 shares of company stock valued at $3,518,177. Insiders own 0.84% of the company's stock.

Laboratory Co. of America Stock Performance

Shares of Laboratory Co. of America stock traded up $2.14 during trading hours on Monday, hitting $230.45. 965,919 shares of the company were exchanged, compared to its average volume of 633,708. The business has a 50-day moving average of $235.30 and a 200-day moving average of $235.28. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $258.59. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $19.28 billion, a price-to-earnings ratio of 26.13, a P/E/G ratio of 1.71 and a beta of 0.99.

Laboratory Co. of America (NYSE:LH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, analysts expect that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 11th. Stockholders of record on Thursday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.25%. Laboratory Co. of America's dividend payout ratio (DPR) is presently 32.65%.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.